ZA201700069B - Inhibitors of lysine specific demethylase-1 - Google Patents

Inhibitors of lysine specific demethylase-1

Info

Publication number
ZA201700069B
ZA201700069B ZA2017/00069A ZA201700069A ZA201700069B ZA 201700069 B ZA201700069 B ZA 201700069B ZA 2017/00069 A ZA2017/00069 A ZA 2017/00069A ZA 201700069 A ZA201700069 A ZA 201700069A ZA 201700069 B ZA201700069 B ZA 201700069B
Authority
ZA
South Africa
Prior art keywords
inhibitors
specific demethylase
lysine specific
lysine
demethylase
Prior art date
Application number
ZA2017/00069A
Other languages
English (en)
Inventor
Marvin Veal James
Alan Stafford Jeffrey
Kanouni Toufike
K Chen Young
Original Assignee
Celgene Quanticel Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54938856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201700069(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Quanticel Res Inc filed Critical Celgene Quanticel Res Inc
Publication of ZA201700069B publication Critical patent/ZA201700069B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyamides (AREA)
ZA2017/00069A 2014-06-27 2017-01-04 Inhibitors of lysine specific demethylase-1 ZA201700069B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462018365P 2014-06-27 2014-06-27
PCT/US2015/038089 WO2015200843A1 (en) 2014-06-27 2015-06-26 Inhibitors of lysine specific demethylase-1

Publications (1)

Publication Number Publication Date
ZA201700069B true ZA201700069B (en) 2018-04-25

Family

ID=54938856

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/00069A ZA201700069B (en) 2014-06-27 2017-01-04 Inhibitors of lysine specific demethylase-1

Country Status (28)

Country Link
US (3) US10011583B2 (cg-RX-API-DMAC7.html)
EP (1) EP3160956B1 (cg-RX-API-DMAC7.html)
JP (2) JP6587241B2 (cg-RX-API-DMAC7.html)
KR (1) KR102438302B1 (cg-RX-API-DMAC7.html)
CN (1) CN106660987B (cg-RX-API-DMAC7.html)
AU (2) AU2015279591A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016030697B1 (cg-RX-API-DMAC7.html)
CA (1) CA2953810C (cg-RX-API-DMAC7.html)
CL (1) CL2016003350A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017000362A2 (cg-RX-API-DMAC7.html)
CY (1) CY1123475T1 (cg-RX-API-DMAC7.html)
DK (1) DK3160956T3 (cg-RX-API-DMAC7.html)
EA (1) EA030946B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17005635A (cg-RX-API-DMAC7.html)
ES (1) ES2812626T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20201337T1 (cg-RX-API-DMAC7.html)
HU (1) HUE050564T2 (cg-RX-API-DMAC7.html)
IL (1) IL249733B (cg-RX-API-DMAC7.html)
LT (1) LT3160956T (cg-RX-API-DMAC7.html)
MX (1) MX376632B (cg-RX-API-DMAC7.html)
PL (1) PL3160956T3 (cg-RX-API-DMAC7.html)
PT (1) PT3160956T (cg-RX-API-DMAC7.html)
RS (1) RS60658B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201911220TA (cg-RX-API-DMAC7.html)
SI (1) SI3160956T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000443T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015200843A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201700069B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016002496B1 (pt) 2013-08-06 2022-07-12 Imago Biosciences Inc. Composto e composição farmacêutica
LT3160956T (lt) 2014-06-27 2020-09-10 Celgene Quanticel Research, Inc. Lizinui specifinės demetilazės-1 inhibitoriai
EA201891526A3 (ru) * 2014-07-03 2019-05-31 Селджен Квонтисел Рисёрч, Инк. Ингибиторы лизин-специфической деметилазы-1
ES3005884T3 (en) 2015-02-12 2025-03-17 Imago Biosciences Inc A kdm1a inhibitor and its use in therapy
US20180284095A1 (en) 2015-06-12 2018-10-04 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
CA3017411C (en) 2016-03-15 2024-06-25 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for use in the treatment of solid tumors
EP3430015B9 (en) 2016-03-16 2025-12-31 Oryzon Genomics, S.A. METHODS FOR DETERMINING THE ENGAGEMENT OF A KDM1A TARGET AND CORRESPONDING USEFUL CHEMOPROBE
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2018035259A1 (en) 2016-08-16 2018-02-22 Imago Biosciences, Inc. Methods and processes for the preparation of kdm1a inhibitors
US20190256930A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
JP7089506B2 (ja) * 2017-04-10 2022-06-22 三井化学アグロ株式会社 ピリドン化合物を有効成分として含有する抗真菌剤およびその使用方法
JP2020121925A (ja) * 2017-04-10 2020-08-13 三井化学アグロ株式会社 ピリドン化合物とキノリン系化合物を含有する有害生物防除組成物および有害生物の防除方法、ならびに新規キノリン系化合物
JP7071962B2 (ja) * 2017-04-10 2022-05-19 三井化学アグロ株式会社 ピリドン化合物と有害生物防除剤を含有する有害生物防除組成物および有害生物の防除方法
AU2018309372B2 (en) 2017-08-03 2024-08-15 Oryzon Genomics, S.A. Methods of treating behavior alterations
JP7265275B2 (ja) * 2018-03-21 2023-04-26 スージョウ プーヘー バイオファーマ カンパニー リミテッド Shp2阻害剤およびその使用
AU2019265022B2 (en) * 2018-05-11 2024-08-15 Imago Biosciences, Inc. KDM1A inhibitors for the treatment of disease
AU2020242302B2 (en) 2019-03-20 2025-10-30 Oryzon Genomics, S.A. Methods of treating borderline personality disorder
CN113631164A (zh) 2019-03-20 2021-11-09 奥莱松基因组股份有限公司 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
JP2022546908A (ja) 2019-07-05 2022-11-10 オリゾン・ゲノミクス・ソシエダッド・アノニマ Kdm1a阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
AU2022254484A1 (en) 2021-04-08 2023-11-09 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
EP4419504A4 (en) * 2021-10-18 2025-09-03 Imago Biosciences Inc KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
JP2025516648A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Lsd1阻害薬を用いるnf1変異腫瘍の治療法
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
KR20250109775A (ko) 2022-11-24 2025-07-17 오리존 지노믹스 에스.에이. 암 치료를 위한 lsd1 억제제 및 메닌 억제제의 조합

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1861399B1 (en) 2005-03-14 2011-12-14 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
BRPI0711674A2 (pt) * 2006-06-21 2011-11-16 Du Pont Método de inibição da proliferação indesejada, composto, composição e método de inibição
HRP20141174T1 (hr) * 2007-06-27 2015-02-13 Astrazeneca Ab Derivati pirazinona i njihova uporaba za lijeäśenje bolesti pluä†a
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2012013727A1 (en) * 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
JP6215315B2 (ja) 2012-06-12 2017-10-18 アッヴィ・インコーポレイテッド ピリジノンおよびピリダジノン誘導体
FI3080100T3 (fi) * 2013-12-11 2023-03-15 Celgene Quanticel Res Inc Lysiinispesifisen demetylaasi-1:n estäjät
CN103804312B (zh) * 2014-02-17 2016-04-20 四川百利药业有限责任公司 一类氮杂环化合物及其制备方法和用途
HRP20220096T1 (hr) * 2014-05-01 2022-04-15 Celgene Quanticel Research, Inc. Inhibitori lizin specifične demetilaze-1
LT3160956T (lt) 2014-06-27 2020-09-10 Celgene Quanticel Research, Inc. Lizinui specifinės demetilazės-1 inhibitoriai

Also Published As

Publication number Publication date
EA030946B1 (ru) 2018-10-31
US20170137402A1 (en) 2017-05-18
SMT202000443T1 (it) 2020-09-10
EP3160956B1 (en) 2020-05-27
MX2017000179A (es) 2017-05-01
RS60658B1 (sr) 2020-09-30
CN106660987A (zh) 2017-05-10
AU2015279591A1 (en) 2017-01-19
DK3160956T3 (da) 2020-08-31
LT3160956T (lt) 2020-09-10
US10011583B2 (en) 2018-07-03
BR112016030697A2 (pt) 2018-07-17
EP3160956A1 (en) 2017-05-03
ES2812626T3 (es) 2021-03-17
JP6587241B2 (ja) 2019-10-09
KR102438302B1 (ko) 2022-08-30
MX376632B (es) 2025-03-07
JP2017519781A (ja) 2017-07-20
KR20170018913A (ko) 2017-02-20
US11028066B2 (en) 2021-06-08
US20200172506A1 (en) 2020-06-04
HRP20201337T1 (hr) 2020-11-27
IL249733A0 (en) 2017-02-28
SI3160956T1 (sl) 2020-11-30
HUE050564T2 (hu) 2020-12-28
CA2953810C (en) 2022-07-12
CA2953810A1 (en) 2015-12-30
AU2019261771B2 (en) 2020-09-24
JP2019167345A (ja) 2019-10-03
IL249733B (en) 2020-07-30
US10597376B2 (en) 2020-03-24
EA201692513A1 (ru) 2017-05-31
CY1123475T1 (el) 2022-03-24
CO2017000362A2 (es) 2017-04-10
CN106660987B (zh) 2020-11-06
EP3160956A4 (en) 2018-01-10
ECSP17005635A (es) 2017-03-31
CL2016003350A1 (es) 2018-05-11
PL3160956T3 (pl) 2020-11-30
JP6851418B2 (ja) 2021-03-31
US20180273505A1 (en) 2018-09-27
SG11201610866PA (en) 2017-01-27
WO2015200843A1 (en) 2015-12-30
AU2019261771A1 (en) 2019-11-28
BR112016030697B1 (pt) 2023-03-21
SG10201911220TA (en) 2020-02-27
PT3160956T (pt) 2020-09-01

Similar Documents

Publication Publication Date Title
IL272130B (en) Inhibitors of specific lysine demethylase-1
IL250876A0 (en) Inhibitors of specific lysine demethylase-1
ZA201607613B (en) Inhibitors of lysine specific demethylase-1
ZA201700069B (en) Inhibitors of lysine specific demethylase-1
ZA201700072B (en) Inhibitors of lysine specific demethylase-1
PL3204352T3 (pl) Inhibitory gingipainy lizynowej
HK1234047A1 (en) Inhibitors of lysine specific demethylase-1
HK1231134A1 (en) Inhibitors of lysine specific demethylase-1
HK1231843A1 (en) Inhibitors of lysine specific demethylase-1